Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma

Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database

(2013) A. J. Olszewski et al.   ANNALS OF ONCOLOGY

How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden

(2013) Sandra Eloranta et al.   CANCER CAUSES & CONTROL

Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy

(2013) C. Kalpadakis et al.   ONCOLOGIST

Survival outcomes with and without splenectomy in splenic marginal zone lymphoma

(2012) Adam J. Olszewski   AMERICAN JOURNAL OF HEMATOLOGY

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma

(2012) Monica Else et al.   BRITISH JOURNAL OF HAEMATOLOGY

Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases

(2012) Carlos Montalbán et al.   BRITISH JOURNAL OF HAEMATOLOGY

Survival of patients with marginal zone lymphoma

(2012) Adam J. Olszewski et al.   CANCER

Comparative Effectiveness Research in Oncology Methodology: Observational Data

(2012) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration

(2011) Amanda R. Patrick et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas

(2011) Cristina Robledo et al.   PLoS One

Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study

(2010) T. Sturmer et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

How I diagnose and treat splenic lymphomas

(2010) E. Iannitto et al.   BLOOD

Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group

(2010) M. Salido et al.   BLOOD

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

(2010) M. D. Danese et al.   BLOOD

InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions

(2010) J. J. Turner et al.   BLOOD

Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Amy J. Davidoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Competing Risk of Death: An Important Consideration in Studies of Older Adults

(2010) Sarah D. Berry et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data

(2010) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab

(2010) Michael Bennett et al.   SEMINARS IN HEMATOLOGY

Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)

(2009) G. Cervetti et al.   ANNALS OF ONCOLOGY

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

(2009) Jennifer R. Brown et al.   BRITISH JOURNAL OF HAEMATOLOGY

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE